Fecal Incontinence – Pipeline Review, 2019

Fecal Incontinence refers to a medical condition in which the individual with the condition is unable to control their bowel movements. Due to some underlying conditions, the feces or stools leak from the rectum and the condition may range in terms of its severity, which may include the loss of total bowel control. Fecal Incontinence is a common medical condition, with around 18 million individuals or 1 in 12 adults in the United States suffering from the condition. The two types of fecal incontinence are passive soiling and urge bowel incontinence.

A number of treatment approaches exist for fecal incontinence which includes medications, bowel training, dietary changes, surgical procedures, and biofeedback. In terms of medications, laxatives, anti-diarrheal medications and medications that decrease bowel motility are administered. If the other treatment options have failed, surgical procedures such as sphincteroplasty, stimulated graciloplasty (gracilis muscle transplant) and sphincter replacement may be undertaken.

Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for fecal incontinence. For instance; AMDC, which is being studied by Cook MyoSite (Cook Group Incorporated), is currently in phase-2 clinical trials for the autologous cell therapy for the treatment of fecal incontinence.

At present, around 64% of the pipeline candidates for fecal incontinence are in the phase-3 and phase-4 stages combined. Majority of the studies are sponsored by industry.

Report Description

The report on ‘Fecal Incontinence – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Fecal Incontinence. The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Fecal Incontinence.

The report on ‘Fecal Incontinence – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.

Report Scope

• Thorough assessment of the pipeline products by areas such as development stage; route of administration; drug class; indication; sponsor; molecule type and drug target
• Comprehensive profiles of the pipeline products with details such as company overview; product description; R&D status; development activities; mechanism of action; molecule type; development stage; indications; funding and route of administration
• Overview of dormant and discontinued pipeline products
• Key insights in relation to the epidemiology of conditions being treated by the pipeline products and overview of the addressable or current market for the pipeline products
• Overview of the latest developments; news articles, press releases, and relevant conferences

Report Methodology

• All pipeline reports are built through the analysis of data primarily collected through credible desk research sources. Secondary research is supplemented by interviews conducted with key opinion leaders.
• Desk research sources include global and regional clinical trials databases; annual reports, websites, press releases & investor presentations of companies; white papers; news articles; reports published by industry associations; articles/reports published on databases such as NCBI, ResearchGate; internal databases

Reasons to Buy this Report

• Develop effective growth strategies based on a comprehensive overview of the R&D activity and pipeline products for Fecal Incontinence
• Identify emerging players or competition in the market based on pipeline products and develop strategies to counter the emergence of these players
• Identify the focus of leading players in relation to R&D for Fecal Incontinence
• Identify potential companies from a partnership or acquisition point of view based on current synergy in R&D activities or strategies to diversify R&D focus to drive growth in business
• Analyze the reasons behind dormant and discontinued products to make changes in the R&D focus if necessary